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Morgan PT, Bailey SJ, Banks RA, Fulford J, Vanhatalo A,
Jones AM. Contralateral fatigue during severe-intensity single-leg
exercise: influence of acute acetaminophen ingestion. Am J Physiol
Regul Integr Comp Physiol 317: R346–R354, 2019. First published
May 29, 2019; doi:10.1152/ajpregu.00084.2019.—Exhaustive single-
leg exercise has been suggested to reduce time to task failure (Tlim)
during subsequent exercise in the contralateral leg by exacerbating
central fatigue development. We investigated the influence of acet-
aminophen (ACT), an analgesic that may blunt central fatigue
development, on Tlim during single-leg exercise completed with
and without prior fatiguing exercise of the contralateral leg. Four-
teen recreationally active men performed single-leg severe-intensity
knee-extensor exercise to Tlim on the left (Leg1) and right (Leg2) legs
without prior contralateral fatigue and on Leg2 immediately following
Leg1 (Leg2-CONTRA). The tests were completed following ingestion of
1-g ACT or maltodextrin [placebo (PL)] capsules. Intramuscular
phosphorus-containing metabolites and substrates and muscle activa-
tion were assessed using 31P-MRS and electromyography, respec-
tively. Tlim was not different between Leg1ACT and Leg1PL conditions
(402 101 vs. 390 106 s, P  0.11). There was also no difference
in Tlim between Leg2ACT-CONTRA and Leg2PL-CONTRA (324 85 vs.
311 92 s, P  0.10), but Tlim was shorter in Leg2ACT-CONTRA and
Leg2PL-CONTRA than in Leg2CON (385 104 s, both P 0.05). There
were no differences in intramuscular phosphorus-containing metabo-
lites and substrates or muscle activation between Leg1ACT and Leg1PL
and between Leg2ACT-CONTRA and Leg2PL-CONTRA (all P  0.05).
These findings suggest that levels of metabolic perturbation and
muscle activation at Tlim are not different during single-leg severe-
intensity knee-extensor exercise completed with or without prior
fatiguing exercise of the contralateral leg. Despite contralateral fa-
tigue, ACT ingestion did not alter neuromuscular responses, muscle
metabolites, or exercise performance.
intramuscular metabolites; intramuscular substrates; nonlocal muscle
fatigue; 31P-magnetic resonance spectroscopy; Paracetamol
INTRODUCTION
The mechanisms of exercise-induced fatigue can be attrib-
uted to processes within the central nervous system, termed
central fatigue, and within the contractile elements of the
working muscle, termed peripheral fatigue. It is now recog-
nized that peripheral and central fatigue development are
interlinked, in part, via group III/IV muscle afferent feedback
(25). Empirical support for a role of group III/IV muscle
afferent feedback in modulating the mechanisms of neuromus-
cular fatigue is provided by reports that inhibition of group
III/IV muscle afferent feedback, via lumbar intrathecal admin-
istration of fentanyl, lowers central fatigue development and
results in increased skeletal muscle metabolic perturbation
[greater and/or more rapid increases in ADP and Pi accumu-
lation and declines in phosphocreatine (PCr) and pH] and, thus,
peripheral fatigue development (1, 2, 8, 10–12, 39–41). Con-
versely, prior fatiguing single-limb exercise has been reported
to accentuate central fatigue development and lead to lower
peripheral fatigue development during subsequent fatiguing
exercise in a contralateral or nonlocal (previously rested)
muscle group, when group III/IV muscle afferent feedback
would be expected to be elevated (3, 22, 23, 26, 34, 41).
However, the underlying mechanisms of nonlocal muscle fa-
tigue, including the effect of prior fatiguing single-limb exer-
cise on skeletal muscle metabolic perturbation during subse-
quent fatiguing exercise in a contralateral or nonlocal muscle
group, have yet to be resolved (see Ref. 23 for review).
Moreover, while lumbar intrathecal administration of fentanyl
and prior fatigue of a contralateral or nonlocal muscle group
can alter group III/IV muscle afferent feedback and the phys-
iological bases of exercise-induced neuromuscular fatigue
(1–3, 8, 10–12, 22, 26, 28, 29, 34), the effect of such inter-
ventions on exercise performance is equivocal. Specifically,
while some studies indicate that exercise performance is al-
tered in these situations, i.e., enhanced with fentanyl (3) or
impaired following contralateral fatigue (14, 22, 29, 34, 42),
others report no significant effect (1, 2, 8, 10, 12, 16, 21, 35,
43, 46).
An emerging body of evidence suggests that oral ingestion
of acetaminophen (ACT) can blunt the development of exer-
cise-induced neuromuscular fatigue and improve exercise ca-
pacity and/or performance (19, 30–32). It is generally accepted
that the principal mechanism of action of ACT is the inhibition
of cyclooxygenase, the enzyme that catalyzes the synthesis of
prostaglandins from arachidonic acid (4). Since prostaglandins
sensitize nociceptors (37, 38) and since blocking cyclooxygen-
ase attenuates group III/IV muscle afferent discharge during
dynamic exercise (24), these mechanisms might account for
reports of increased work output for the same level of per-
ceived pain and exertion (19, 30) and elevated muscle activa-
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tion (31, 32) during exercise after ACT ingestion. Therefore,
ACT administration might be ergogenic by reducing, but not
abolishing, the net magnitude of group III/IV muscle afferent
feedback, leading to a blunting of exercise-induced central
fatigue. Since ACT appears to attenuate exercise-induced neu-
romuscular fatigue by abating aspects of central fatigue devel-
opment (19, 30–32), ACT might be more effective at lowering
exercise-induced neuromuscular fatigue following prior ex-
haustive exercise in a contralateral limb. However, the effects
of ACT ingestion on exercise-induced fatigue development and
its underlying mechanisms following prior exercise in a con-
tralateral limb have yet to be investigated.
The purpose of this study was to investigate the effects of
ACT ingestion on exercise-induced neuromuscular fatigue and
some of its underlying mechanisms during single-leg severe-
intensity knee-extensor exercise completed with and without
prior exhaustive severe-intensity knee-extensor exercise in the
contralateral leg. It was hypothesized that 1) prior exhaustive
exercise would impair subsequent exercise tolerance in
the contralateral leg by lowering muscle activation and the
degree of muscle metabolic perturbation [changes in muscle
pH and PCr ([PCr]), ADP ([ADP]), and Pi ([Pi]) concentra-
tions] that could be attained, 2) ACT ingestion would en-
hance single-leg knee-extensor exercise tolerance by increas-
ing muscle activation [higher surface electromyogram (EMG)]
and permitting a greater degree of muscle metabolic perturba-
tion, and 3) completion of prior exercise by the contralateral
leg would lead to a greater enhancement of exercise tolerance
following ACT ingestion.
MATERIALS AND METHODS
Subjects. Fourteen active men [age 23.8 (SD 4.7) yr, height
1.80 (SD 0.10) m, body mass 81.6 (SD 14.9) kg] volunteered to
participate in the study. All procedures were approved by the Ethics
Committee of the Department of Sport and Health Sciences, Univer-
sity of Exeter. The study conformed to the principles of the World
Medical Association Declaration of Helsinki. Subjects completed a
health questionnaire that was checked by a medical doctor to ensure
that the subjects could safely consume ACT before performing ex-
haustive exercise. The questionnaire incorporated questions pertaining
to known allergies to medications, current intake of medication, and
prior use of ACT, as well as any history of illnesses, cigarette and
illegal drug use, alcohol consumption, and chronic illnesses (personal
and family history). Before each visit, subjects were required to
refrain from caffeine (for 12 h), strenuous exercise and alcohol (for
24 h), and analgesics and any form of anti-inflammatory drug (for
the duration of the experiment) and to arrive in a fully rested, hydrated
state. With the exception of these restrictions, subjects were instructed
to maintain their usual diet and exercise regimen during the study. All
tests were performed at a similar time of day (2 h).
Preexperimental procedures. Subjects visited the laboratory on 12
occasions over an 8- to 12-wk period to complete the experimental
testing, with 72 h separating consecutive tests (Fig. 1). The exper-
imental testing incorporated four preexperimental trials (visits 1–4)
and eight experimental trials (visits 5–12). Visits 1–4 were completed
within a replica of an MRI scanner (with no magnetic field present).
Initially, subjects completed a single-limb incremental test on the left
leg (visit 1, Leg1) and right leg (visit 2, Leg2) to task failure to
establish the limb-specific work rates that would be applied in sub-
sequent experimental visits (see below). After these preliminary tests,
subjects completed a familiarization session on visits 3 and 4 that
comprised a single-leg severe-intensity constant work rate (CWR) test
to task failure with the left leg (Leg1), a single-leg severe-intensity
CWR test to task failure with the right leg (Leg2), and a crossover test,
where the Leg1 protocol was repeated and immediately followed by
the trial to assess contralateral fatigue in Leg2 (Leg2-CONTRA proto-
col). Severe-intensity exercise is defined as being above critical power
(33). In these preliminary tests, the Leg1, Leg2, and Leg2 contralateral
(Leg2-CONTRA) protocols were interspersed with 10 min of passive
recovery.
Experimental procedures. During visits 5 and 6, subjects completed
the Leg1 and Leg2 protocols without oral consumption of capsules
(Leg1CON and Leg2CON, respectively). On visits 7 and 8, subjects
completed the crossover limb tests described above 45 min following
consumption of 1 g of maltodextrin [placebo (PL)] to determine time
to task failure (Tlim) values for Leg1 (Leg1PL) and Leg2-CONTRA
(Leg2PL-CONTRA) and 45 min following consumption of 1 g of ACT
to determine Tlim values for Leg1 (Leg1ACT) and Leg2-CONTRA
(Leg2ACT-CONTRA). PL and ACT were administered in the form of
two identically colored capsules. PL consisted of maltodextrin powder
in gelatin capsules designed to have an appearance similar to ACT
without analgesic or antipyretic effects. The oral consumption of PL
and ACT ~45 min before commencement of exercise was selected to
broadly coincide with attainment of the peak plasma ACT concentra-
tion ([ACT]), which occurs ~60 min after ACT ingestion (4, 17), at
the onset of the Leg2-CONTRA tests. The PL and ACT conditions were
administered double-blind in a counterbalanced crossover experimen-
tal design. Visits 5–8 were completed within the bore of an MRI
scanner for assessment of exercise-induced changes in intramuscular
phosphorus-containing substrates and metabolites. Visits 5–8 were
replicated in visits 9–12 within a replica of the MRI scanner (with no
magnetic field present) to assess muscle EMG and ratings of per-
ceived exertion (RPE).
Experimental setup. Exercise tests were performed with subjects in
a prone position within the bore of a 1.5-T superconducting magnet
(Gyroscan Clinical Intera, Philips, The Netherlands) using a custom-
built ergometer for assessment of intramuscular [PCr], [Pi], [ADP],
and pH (visits 5–8) or within a replica of the MRI scanner for
preliminary testing (visits 1–4) and assessment of EMG and RPE
responses (visits 9–12). The subject’s feet were fastened securely to
padded foot braces using Velcro straps and connected to the ergom-
eter load baskets via a rope-and-pulley system. The sprocket arrange-
ment was such that when a bucket containing nonmagnetic weights
was attached, it provided a concentric-only resistive load, allowing for
the performance of rhythmic knee-extension exercise. Single-leg knee
extensions over a distance of 0.22 m were performed continuously
at a constant frequency, which was set in unison with the magnetic
pulse sequence (40 pulses/min) to ensure that the quadriceps muscle
was in the same phase of contraction during each magnetic resonance
pulse acquisition. To prevent displacement of the quadriceps relative
to the magnetic resonance spectroscopy (MRS) coil, Velcro straps
were also fastened over the subject’s thighs, hips, and lower back.
Experimental protocol. To determine peak work rate for each leg,
the subjects initially completed single-leg incremental knee-extensor
exercise on visits 1 and 2 until they were unable to continue the
prescribed work rate, as described previously (44). The load for the
initial increment was 4 kg, which was increased by 0.5 kg/min
thereafter until Tlim. Tlim was recorded when the subjects were unable
to sustain the required contraction frequency for three consecutive
repetitions. After these initial tests, the subjects were familiarized with
the different exercise tests that comprised the experimental testing
protocol. During these visits, a limb-specific, severe-intensity work
rate, which was expected to elicit Tlim in ~5–8 min, was prescribed for
each subject. The work rate initially selected was 80% of the peak
work rate attained in the incremental test, and depending on responses
in the familiarization tests, this was adjusted for each individual to
give the desired exercise duration during subsequent tests.
The experimental exercise protocol consisted of CWR single-leg
severe-intensity knee extension to Tlim. Initially, the subjects com-
pleted single-leg knee-extension exercise for each limb individually
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over two separate laboratory visits. Subsequently, to investigate the
influence of ACT on contralateral leg fatigue, the subjects completed
single-leg knee-extension exercise until task failure with Leg1 fol-
lowed consecutively (3 s) by the identical task with the contralateral
leg (i.e., Leg2). These crossover tests to assess contralateral fatigue in
Leg2 were completed 60 min following consumption of PL and ACT
over two separate laboratory visits. For all trials, the subjects received
strong verbal encouragement to continue for as long as possible, but
they were given no feedback on the elapsed time.
MRS measurements. 31P-MRS data, with a spectral width of
1,500 Hz and 1,000 data points, were acquired every 1.5 s. Phase
cycling with four phase cycles led to a spectrum being acquired
every 6 s. The subsequent spectra were quantified by peak fitting
using the AMARES fitting algorithm in the jMRUI (v3) software
package. Absolute values of [PCr] and [Pi] were subsequently calcu-
lated from the PCr-to-ATP and Pi-to-ATP ratios, with the assumption
of 8.2 mM ATP. Intracellular pH was calculated using the chemical
shift of the Pi spectra relative to the PCr peak. [ADP] was calculated
as described by Kemp et al. (27). In all cases, relative amplitudes were
corrected for partial saturation resulting from the short repetition time
relative to T1 relaxation time via a spectrum consisting of 24 averages
that was acquired with a TR of 20 s before the commencement of
exercise testing.
Electromyography. Throughout visits 9–12, muscle activity of the
right and left vastus lateralis was recorded using active bipolar bar
electrodes with a single differential configuration (model DE2.1,
DelSys, Boston, MA). Initially, the leg was shaved and cleaned with
alcohol to minimize skin impedance. The electrodes were placed over
the respective muscle bellies parallel to the longitudinal axis of each
muscle (Surface EMG for Non-Invasive Assessment of Muscles
guidelines). Double-sided adhesive tape and a hypoallergenic medical
tape were used to ensure stability of the EMG sensor. The position of
the EMG electrodes was measured with respect to the location of the
patella and the anterior superior iliac spine and marked with indelible
ink to ensure placement in the same location on subsequent visits. The
ground electrode was placed over the patella of the respective leg.
The EMG signals were preamplified (1,000), band-pass-filtered
(20–450 Hz; Bagnoli-8, DelSys), and then transferred to a computer
with a sampling frequency of 2 kHz. EMG data were recorded
continuously and digitized synchronously with 16-bit resolution via
an analog-to-digital converter (5-V range, CED 1401 power, Cam-
bridge Electronic Design, Cambridge, UK) using Spike2 software
Fig. 1. Protocol schematic. Visits 1–4 were completed within a replica of the MRI scanner. Subjects completed a single-leg incremental test on the left (L) leg
(visit 1, Leg1) and right (R) leg (visit 2, Leg2). On visits 3 and 4, subjects completed a familiarization session, which comprised a single-leg severe-intensity
constant work rate (CWR) test to task failure with Leg1 and Leg2 and a crossover test where the Leg1 protocol was repeated and immediately followed by the
Leg2 protocol (interspersed with 10 min of passive recovery). During visits 5 and 6, subjects completed the Leg1 and Leg2 protocols, respectively, without oral
consumption of capsules. On visits 7 and 8, subjects commenced the crossover test 45 min following consumption of 1 g of maltodextrin (PL) and 45 min
following consumption of 1 g of acetaminophen (ACT). Visits 5–8 were completed within the bore of an MRI scanner for assessment of intramuscular
phosphorus-containing substrates and metabolites and then replicated within a replica of the MRI scanner (visits 9–12) to assess muscle electromyography (EMG)
and ratings of perceived exertion (RPE). Dashed vertical lines represent the limit of tolerance [i.e., time to task failure (Tlim)] for each trial and/or leg. MRS,
magnetic resonance spectroscopy; PCr, phosphocreatine.
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(Cambridge Electronic Design). During these trials, RPE was mea-
sured at 2-min intervals from the onset of exercise using Borg’s 6–20
scale (9).
Data analysis. Baseline values for [PCr], [Pi], [ADP], and pH were
defined as the mean values measured over the final 60 s of rest (i.e.,
before initiation of the severe-intensity exercise bout). Baseline values
for Leg2 during the crossover protocol (for both PL and ACT) were
calculated during the final 60 s of exhaustive Leg1 exercise. End-
exercise values for these variables were defined as the mean values
measured over the final 30 s of exercise. The changes () in [PCr],
[Pi], [ADP], and pH across the protocol were then calculated as the
difference between end-exercise and baseline values. [PCr], [Pi], and
[ADP] are expressed as absolute concentrations and as percent change
relative to resting baseline (i.e., 100%). The overall rate of change for
[PCr], [Pi], [ADP], and pH was calculated as the difference between
end-exercise and baseline values divided by Tlim. EMG was
average-rectified and normalized to the first 30 s of each trial
(aEMG). For analysis, Tlim values obtained from visits 5– 8 were
used. Visits 9 –12 were used to overlay EMG and RPE responses on
31P-MRS data.
Statistics. Differences in Tlim, baseline and end-exercise aEMG,
and muscle [PCr], [Pi], [ADP], and pH between control limbs (i.e.,
Leg1 vs. Leg2) were assessed using paired-samples t-tests. A two-way
(time  condition) repeated-measures ANOVA was employed to
test for differences in the profiles of muscle [PCr], [Pi], [ADP], and
pH, aEMG (using 30-s mean values), and RPE (using 120-s mean
values). Where the ANOVA revealed a significant main or inter-
action effect, post hoc tests were completed using Bonferroni’s
correction. For calculation of effect size, partial 	2 was used for
omnibus tests. Cohen’s d was used to calculate the effect size for
paired t-tests and post hoc comparisons. Where sphericity was
violated, a Greenhouse-Geisser correction factor was applied. For
all tests, results were considered statistically significant when P 
0.05. Data are presented as means (SD) unless otherwise indicated.
All statistical analyses were conducted using IBM SPSS Statistics
version 24.
RESULTS
There was no difference in Tlim during the Leg1CON [396 (SD
105) s] and Leg2CON [385 (SD 104) s] protocols [P  0.20,
d 0.10, coefficient of variation 2.0 (SD 1.7) %; Fig. 2].
Moreover, there were no differences in [PCr], [Pi], [ADP], pH
(Table 1, Fig. 3), aEMG amplitude (Table 2, Fig. 5), and RPE
(Fig. 6) between Leg1CON and Leg2CON at any time (all P 0.05).
Compared with Leg2CON, Tlim was reduced by 19% when Leg2
was preceded by exhaustive exercise in Leg1 following consump-
tion of PL [Leg2CON and Leg2PL-CONTRA 385 (SD 104) and
311 (SD 92) s, respectively, P  0.01, d 0.76; Fig. 2].
Effect of ACT on single-leg exercise tolerance and contralat-
eral leg fatigue. There was no difference in Tlim between the
Leg1CON [396 (SD 105) s], Leg1ACT [402 (SD 101) s], and
Leg1PL [390 (SD 106) s] conditions (P  0.55, 	2  0.07; Fig.
2). Tlim values were significantly lower for Leg2PL-CONTRA and
Leg2ACT-CONTRA than for Leg2CON (P  0.01, 	2  0.71;
Fig. 2). However, there was no difference in Tlim between
Leg2PL-CONTRA and Leg2ACT-CONTRA [311 (SD 92) and
324 (SD 85) s, respectively, P  0.09, d  0.15, coefficient
of variation  4.9 (SD 5.4) %; Fig. 2].
Muscle metabolic measurements. The [PCr], [Pi], [ADP], and
pH profiles are illustrated in Fig. 3 for Leg1PL and Leg1ACT and in
Fig. 4 for Leg2CON, Leg2PL-CONTRA, and Leg2ACT-CONTRA. There
Fig. 2. Exercise tolerance [time to task failure (exhaustion)] in Leg1CON,
Leg2CON, Leg1PL, Leg2PL-CONTRA, Leg1ACT, and Leg2ACT-CONTRA conditions.
CON, control; PL, placebo; CONTRA, contralateral; ACT, acetaminophen.
Values are means (SD). *Significantly different from Leg1 (P  0.05).
Table 1. Muscle metabolic responses in Leg1CON, Leg1PL, Leg1ACT, Leg2CON, Leg2PL-CONTRA, and Leg2ACT-CONTRA conditions
Leg1CON Leg1PL Leg1ACT Leg2CON Leg2PL-CONTRA Leg2ACT-CONTRA
[PCr]
Baseline, % 100 (0) 100 (0) 100 (0) 100 (0) 92 (5)* 93 (4)*
120 s, % 70 (8) 70 (8) 71 (7) 71 (8) 62 (9)* 63 (7)*
End exercise, % 42 (9) 41 (9) 41 (8) 44 (8) 45 (7) 44 (8)
Rate of change, mmol/s 
0.06 (0.01) 
0.06 (0.03) 
0.06 (0.02) 
0.05 (0.03) 
0.06 (0.04) 
0.06 (0.03)
[Pi]
Baseline, % 100 (0) 100 (0) 100 (0) 100 (0) 125 (24)* 126 (23)
120 s, % 310 (66) 313 (71) 306 (62) 312 (66) 316 (70) 318 (64)
End exercise, % 590 (149) 590 (137) 594 (156) 588 (177) 459 (110)* 460 (109)*
Rate of change, mmol/s 0.05 (0.02) 0.05 (0.02) 0.05 (0.02) 0.05 (0.02) 0.05 (0.02) 0.05 (0.02)
[ADP]
Baseline, % 100 (0) 100 (0) 100 (0) 100 (0) 200 (78)* 201 (77)*
120 s, % 404 (161) 415 (183) 400 (148) 412 (170) 538 (176) 516 (154)*
End-exercise, % 1,028 (386) 1,036 (421) 1,046 (409) 1,024 (401) 980 (316) 978 (312)
Rate of change, mol/s 0.15 (0.08) 0.15 (0.09) 0.14 (0.07) 0.15 (0.09) 0.17 (0.10) 0.15 (0.09)
pH
Baseline 7.04 (0.01) 7.03 (0.02) 7.05 (0.04) 7.04 (0.03) 7.04 (0.03) 7.05 (0.02)
120 s 6.96 (0.09) 6.94 (0.07) 6.92 (0.08) 6.95 (0.08) 6.93 (0.10) 6.94 (0.08)
End-exercise 6.77 (0.18) 6.76 (0.15) 6.76 (0.16) 6.83 (0.15) 6.83 (0.20) 6.80 (0.15)
Values are means (SD) of 14 male subjects who performed single-leg severe-intensity knee-extensor exercise to task failure on the left (Leg1) and right (Leg2)
legs without prior contralateral fatigue and on Leg2 immediately following Leg1 (Leg2-CONTRA). PL, placebo; ACT, acetaminophen; [PCr], phosphocreatine
concentration; [Pi], Pi concentration; [ADP], ADP concentration. *P  0.05 vs. Leg2CON.
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were no significant differences in [PCr], [Pi], [ADP], or pH at any
time points between Leg1CON and Leg2CON (all P  0.05; Table
1, Fig. 3). Similarly, there were no significant differences in
end-exercise [PCr], [ADP], and pH between the Leg2CON,
Leg2PL-CONTRA, and Leg2ACT-CONTRA conditions (Table 1,
Fig. 4). However, end-exercise [Pi] was significantly lower
in Leg2PL-CONTRA and Leg2ACT-CONTRA than in Leg2CON
(P  0.05, 	2  0.89; Table 1, Fig. 4). Baseline [PCr] was
significantly higher (P  0.0001, 	2  3.04), and [Pi] (P 
0.01, 	2  2.13) and [ADP] (P  0.01, 	2  2.55; Table 1,
Fig. 4) were significantly lower, in Leg2CON than Leg2PL-CONTRA
and Leg2ACT-CONTRA, respectively. The rates of change for [Pi],
[PCr], [ADP], and pH were not different between Leg2CON,
Leg2PL-CONTRA, and Leg2ACT-CONTRA conditions.
Electromyography. aEMG amplitude of vastus lateralis
rose significantly from the first minute of exercise to end
exercise in all conditions (P  0.01, 	2  3.8; Fig. 5).
However, there were no differences in aEMG between
Leg1CON, Leg1PL, and Leg1ACT at Tlim (Table 2, Fig. 5).
End-exercise aEMG in Leg2CON was also not different from
Leg2PL-CONTRA and Leg2ACT-CONTRA (Table 2, Fig. 5). How-
ever, absolute aEMG was elevated at the start of Leg2PL-
CONTRA and Leg2ACT-CONTRA compared with Leg2CON (P 0.01,
	2 0.58; Table 2, Fig. 5).
Ratings of perceived exertion. RPE increased in all trials
following the onset of exercise (Fig. 6). However, there were
no differences in RPE between Leg1CON, Leg1PL, and Leg1ACT
at any time point (P 0.72, 	2  0.08; Fig. 6). The rate of rise
and the end-exercise RPE were also not different between the
Leg2CON trial and the Leg2PL-CONTRA and Leg2ACT-CONTRA trials
(P  0.66, 	2 0.18). However, at the onset of exercise, RPE
was significantly higher in Leg2PL-CONTRA and Leg2ACT-CONTRA
than in Leg2CON (P  0.01, 	2 0.55; Fig. 6). Specifically,
during the first 2 min of exercise, RPE was elevated 14% and 13%
in Leg2PL-CONTRA and Leg2ACT-CONTRA, respectively, compared
with Leg2CON (P  0.01). There were no differences in RPE at
any time points between Leg2PL-CONTRA and Leg2ACT-CONTRA
(P  0.60, 	2 0.21; Fig. 6).
Fig. 3. Intramuscular phosphocreatine (PCr) concentration ([PCr]; A), Pi concentration ([Pi]; B), ADP concentration ([ADP]; C), and pH (D) during
severe-intensity single-leg knee-extensor exercise in the left leg following ingestion of placebo (Leg1PL) and acetaminophen (Leg1ACT). Values are group
means  SE.
Table 2. EMG responses of the vastus lateralis in Leg1CON, Leg1PL, Leg1ACT, Leg2CON, Leg2PL-CONTRA, and Leg2ACT-CONTRA
conditions
Leg1CON Leg1PL Leg1ACT Leg2CON Leg2PL-CONTRA Leg2ACT-CONTRA
EMGRMS amplitude
Baseline, mV 0.04 (0.01) 0.04 (0.02) 0.04 (0.02) 0.04 (0.02) 0.05 (0.02)* 0.05 (0.02)*
End exercise, % 229 (54) 224 (43) 238 (51) 234 (52) 226 (58) 242 (52)
120 s, % 150 (27) 160 (25) 166 (26) 158 (29) 155 (32) 158 (34)
Values are means (SD) of 10 subjects who performed single-leg severe-intensity knee-extensor exercise to task failure on the left (Leg1) and right (Leg2) legs
without prior contralateral fatigue and on Leg2 immediately following Leg1 (Leg2-CONTRA). PL, placebo; ACT, acetaminophen; RMS, root mean square. *P 
0.05 vs. Leg2CON.
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DISCUSSION
The principal original finding of this study was that while
Tlim was lower during severe-intensity single-leg knee-exten-
sor exercise after completion of prior fatiguing exercise in the
contralateral leg, this effect was not mitigated by acute ACT
ingestion. We found no differences in the rates of change or
end-exercise values for skeletal muscle activation (via EMG),
metabolic perturbation (via 31P-MRS), and perception of effort
(via RPE) during exercise after prior contralateral leg fatigue
following ACT and PL ingestion. Moreover, there were no
differences in Tlim, skeletal muscle activation, metabolic per-
turbation, and RPE during single-leg exercise without comple-
tion of prior fatiguing exercise by the contralateral leg follow-
ing ACT and PL ingestion. These findings do not support our
experimental hypotheses and suggest that acute ingestion of 1
g of ACT does not improve Tlim, skeletal muscle activation,
metabolic perturbation, or perceived exertion during single-leg
severe-intensity knee-extensor exercise completed with or
without prior fatiguing exercise by the contralateral leg.
In the present study, Tlim was shorter in the Leg2PL-CONTRA
than the Leg2CON protocol, indicative of an earlier task failure
after completion of exhaustive exercise in the contralateral leg
Fig. 4. Intramuscular phosphocreatine (PCr) concentration ([PCr]; A), Pi concentration ([Pi]; B), ADP concentration ([ADP]; C), and pH (D) during
severe-intensity single-leg knee-extensor exercise in the right control leg (Leg2CON) and in the right leg following prior exhaustive exercise in the left leg after
ingestion of placebo (Leg2PL-CONTRA) and ACT (Leg2ACT-CONTRA). Values are group means SE. *Time to task failure (Tlim) significantly different from
Leg2PL-CONTRA and Leg2ACT-CONTRA (P  0.05); #[Pi] significantly different from Leg2PL-CONTRA and Leg2ACT-CONTRA (P  0.05).
Fig. 5. A: surface EMG of the vastus lateralis during severe-intensity single-leg knee-extensor exercise in the left leg following ingestion of placebo (Leg1PL)
and acetaminophen (Leg1ACT). B: surface EMG of the vastus lateralis during severe-intensity single-leg knee-extensor exercise in the right control leg (Leg2CON)
and in Leg2 following prior exhaustive exercise in Leg1 after ingestion of placebo (Leg2PL-CONTRA) and acetaminophen (Leg2ACT-CONTRA). Mean values for
average rectified EMG during each muscle contraction were calculated and averaged over each 30-s period. Values are group means SE relative to the first
30 s of each trial. *Time to task failure (Tlim) significantly different from Leg2PL-CONTRA and Leg2ACT-CONTRA (P  0.05).
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compared with no prior fatiguing contralateral leg exercise.
This observation is consistent with some (3, 14, 22, 29, 34, 42),
but not all (16, 21, 35, 43, 46), previous studies reporting
greater fatigue development after prior contralateral or nonlo-
cal muscle fatigue. While the neuromuscular bases of con-
tralateral fatigue development have yet to be fully resolved
(23), there is evidence that greater central fatigue makes an
important contribution to this phenomenon (3). In the current
study, RPE was higher at baseline and over the initial stages of
the Leg2PL-CONTRA test than the Leg2CON test, leading to an
earlier attainment of peak RPE and Tlim, consistent with
previous observations (3) and the notion that afferent feedback
may contribute to increased pain and effort sensation (1, 20).
Amann et al. (3) reported a lower EMG response at task failure
and reduced peripheral fatigue development after prior con-
tralateral leg fatigue. Although the EMG amplitude was not
different at task failure in the current study between the
Leg2CON and Leg2PL-CONTRA tests, baseline EMG was elevated
in the Leg2PL-CONTRA condition, presumably due to isometric
stabilization, leading to the earlier attainment of the same peak
EMG amplitude. It should be noted here that EMG responses
were normalized to the initial exercise values in the present
study and in the study of Amann et al. (3). The greater muscle
activation in the nonexercising contralateral leg during the
baseline “resting” period in the Leg2PL-CONTRA condition was
accompanied by lower muscle [PCr] and higher muscle [Pi]
and [ADP] than in the Leg2CON condition. Since there were no
differences in muscle [PCr] and [ADP] at Tlim and since the
rates of change in [PCr] and [ADP] were not different between
the Leg2CON and Leg2PL-CONTRA tests, the muscle [PCr] nadir
and [ADP] peak were attained earlier in the Leg2PL-CONTRA
test. These observations cohere with reports that the end-
exercise values of muscle [PCr], [ADP], and pH are consistent
when several bouts of exhaustive exercise of differing duration
are completed within the severe-intensity domain (7, 45) and
when Tlim is altered via prior passive heating of the legs (6) or
by hyperoxic gas inhalation (45). Interestingly, however, and
despite a higher baseline muscle [Pi] in the Leg2PL-CONTRA
than the Leg2CON condition, muscle [Pi] was lower at task
failure in the Leg2PL-CONTRA test. These novel observations
suggest that the ergolytic effect of prior contralateral fatigue
may be related, at least in part, to a limitation in the attainment
of peak intramuscular [Pi].
It is unclear why prior contralateral leg fatigue limited the
attainment of peak [Pi] in the Leg2PL-CONTRA condition
compared with the Leg2CON condition, whereas the peak
[ADP] and the nadir in pH and [PCr] were not different
between these conditions. However, our observations of a
limited peak perturbation of muscle [Pi], but not pH, [PCr],
and [ADP], when group III/IV muscle afferent feedback
would be expected to be elevated via prior contralateral
fatigue (3) are in accord with studies from others who
observed greater peak perturbation of muscle [Pi], but not
pH, [PCr], and [ADP], when group III/IV muscle afferent
feedback was abolished via lumbar intrathecal administra-
tion of fentanyl (8, 11, 12). Together, these complementary
observations suggest that intramuscular phosphorus-con-
taining metabolites and substrates may not respond in a
uniform manner to manipulations in skeletal muscle group
III/IV afferent feedback and that muscle [Pi] might be the
more sensitive marker of muscle metabolic strain. However,
it should be acknowledged that since within-test variability
is greater for contracting skeletal muscle [Pi] than for pH,
[PCr], and [ADP] (15), further research is required to verify
these observations.
Although the completion of prior single-leg fatiguing
exercise lowered Tlim during subsequent exercise in the
contralateral leg in the current study, there were no differ-
ences between the Leg2ACT-CONTRA and Leg2PL-CONTRA con-
ditions in Tlim, RPE, or muscle activation and phosphorus-
containing metabolites and substrates. Similarly, and also in
contrast to our hypothesis, acute ACT ingestion did not alter
Tlim, RPE, or muscle activation, pH, [PCr], [ADP], or [Pi]
during single-leg severe-intensity knee-extensor exercise
completed without prior fatiguing exercise in the contralat-
eral leg: these responses were similar between the Leg1CON,
Leg1PL, and Leg1ACT conditions. These findings conflict
with reports that acute ACT consumption can improve
exercise performance by increasing work output for the
same level of pain and effort sensation (19, 30) and by
increasing muscle activation (31, 32).
Experimental considerations. The lack of an ergogenic ef-
fect of ACT administration in the current study might be due to
differences in the ACT administration procedure compared
with previous studies reporting improved performance and
delayed neuromuscular fatigue development (19, 30–32). In
Fig. 6. A: ratings of perceived exertion (RPE) during severe-intensity single-leg knee-extensor exercise of the left leg following ingestion of placebo (Leg1PL)
and acetaminophen (Leg1ACT). B: RPE during severe-intensity single-leg knee-extensor exercise of the right control leg (Leg2CON) and the right leg following
prior exhaustive exercise in the left leg after ingestion of placebo (Leg2PL-CONTRA) and acetaminophen (Leg2ACT-CONTRA). Values are group means SE. *Time
to task failure (Tlim) significantly different from Leg2PL-CONTRA and Leg2ACT-CONTRA (P  0.05); #RPE significantly different from Leg2CON (P  0.05).
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the present study, ACT was ingested 45 min before the start of
the Leg1ACT test, which immediately transitioned to the
Leg2ACT-CONTRA protocol, the primary focus of the current
study. Since peak plasma [ACT] is attained ~60 min after oral
ACT ingestion (4, 17), we elected to administer ACT such that
peak plasma [ACT] was expected to coincide with the onset of
the Leg2ACT-CONTRA, rather than the Leg1ACT, protocol. This
might account for the lack of an ergogenic effect of ACT
during the Leg1ACT protocol compared with other studies in
which ACT was administered 60 min before the performance
trial (19, 30–32). Therefore, we cannot exclude the possibility
that earlier ACT ingestion (18), at the same or a greater dose
(19, 30), might have resulted in improved single-leg severe-
intensity exercise tolerance. However, interstudy differences in
participant characteristics (i.e., training status, motivation, and
responsiveness to analgesic medication) may have contributed
to the differences in ergogenicity observed following ACT
ingestion between the current study and some previous studies
(19, 30–32).
In addition to differences in the ACT dosing procedure, the
lack of an ergogenic effect of ACT administration in the
current study might be linked to the nature of the fatiguing
exercise test administered. Our subjects completed continuous
single-leg severe-intensity knee-extensor exercise until task
failure with no predetermined end point (i.e., an “open-loop”
exercise test). This differs from situations in which ACT
ingestion has been reported to be ergogenic, such as comple-
tion of a fixed-distance (16.1-km) time trial (30), a fixed
number of maximal-effort repetitions (19, 31), or a fixed
duration of maximal effort (32), all of which have a predeter-
mined end point (i.e., a “closed-loop” exercise task). More-
over, since exercise-induced pain sensation is positively asso-
ciated with exercise intensity (5, 13) and since ACT ingestion
is suggested to be ergogenic by mitigating pain sensation (19,
30), this might account for the lack of improvement in perfor-
mance in the longer-duration, continuous severe-intensity ex-
ercise test we employed compared with the improved exercise
performance that has been reported during maximal-intensity
exercise (19, 31, 32). With regard to contralateral fatigue
development, we cannot exclude the possibility that ACT
might have been effective at attenuating the effects of prior
single-leg fatigue on Tlim during subsequent exercise if a
greater degree of contralateral fatigue had been attained. For
example, Tlim was lowered by 19% in Leg2PL-CONTRA com-
pared with Leg2CON in the current study, whereas Amann et al.
(3) reported a much larger (49%) reduction in Tlim following
contralateral limb fatigue, which would have provided greater
scope for an ergogenic effect with ACT ingestion. Moreover,
since RPE is higher and Tlim is shorter at the same relative
exercise intensity when a larger muscle mass is recruited (36),
it is possible that ACT ingestion might have improved Tlim
during exercise after prior fatigue, had a larger muscle mass
been recruited in either the initial or the subsequent fatiguing
exercise task. Further research is required to assess the exercise
settings in which ACT administration is more or less likely to
be ergogenic, including those with small compared with large
muscle group exercise, in different exercise intensity domains,
and with different pacing profiles (CWR compared with max-
imal and self-paced).
Perspectives and Significance
The completion of prior single-leg fatiguing exercise com-
promised exercise tolerance during subsequent exercise in the
contralateral leg. This ergolytic effect of prior contralateral leg
fatigue was accompanied by elevated baseline RPE, muscle
activation, and [ADP] and lower baseline [PCr], leading to the
earlier attainment of peak (RPE, muscle activation, and [ADP])
or nadir (muscle [PCr]) values in these variables and attain-
ment of a submaximal end-exercise [Pi]. However, acute ACT
ingestion was not effective at lowering perceived exertion,
increasing muscle activation or intramuscular perturbation, or
enhancing Tlim during single-leg severe-intensity exercise
completed with or without prior fatigue in the contralateral leg.
These findings do not support an ergogenic effect of analgesia
during severe-intensity single-leg dynamic contractions.
ACKNOWLEDGMENTS
Present address for S. J. Bailey: School of Sport, Exercise and Health
Sciences, Loughborough University, Epinal Way, Loughborough, Leicester-
shire LE11 3TU, UK.
GRANTS
This research was not sponsored by any funding body external to the
University of Exeter. J. Fulford’s salary was supported via National Institute
for Health Research Grant CRF/2016/10027 to the University of Exeter.
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the authors.
AUTHOR CONTRIBUTIONS
P.T.M., S.J.B., A.V., and A.M.J. conceived and designed research; P.T.M.,
R.A.B., and J.F. performed experiments; P.T.M., R.A.B., and J.F. analyzed
data; P.T.M., S.J.B., J.F., A.V., and A.M.J. interpreted results of experiments;
P.T.M. and R.A.B. prepared figures; P.T.M., S.J.B., and A.M.J. drafted
manuscript; P.T.M., S.J.B., J.F., and A.M.J. edited and revised manuscript;
P.T.M., S.J.B., R.A.B., J.F., A.V., and A.M.J. approved final version of
manuscript.
REFERENCES
1. Amann M, Blain GM, Proctor LT, Sebranek JJ, Pegelow DF, Demp-
sey JA. Implications of group III and IV muscle afferents for high-intensity
endurance exercise performance in humans. J Physiol 589: 5299–5309, 2011.
doi:10.1113/jphysiol.2011.213769.
2. Amann M, Proctor LT, Sebranek JJ, Pegelow DF, Dempsey JA.
Opioid-mediated muscle afferents inhibit central motor drive and limit
peripheral muscle fatigue development in humans. J Physiol 587: 271–
283, 2009. doi:10.1113/jphysiol.2008.163303.
3. Amann M, Venturelli M, Ives SJ, McDaniel J, Layec G, Rossman MJ,
Richardson RS. Peripheral fatigue limits endurance exercise via a
sensory feedback-mediated reduction in spinal motoneuronal output. J
Appl Physiol (1985) 115: 355–364, 2013. doi:10.1152/japplphysiol.
00049.2013.
4. Anderson BJ. Paracetamol (acetaminophen): mechanisms of action. Pae-
diatr Anaesth 18: 915–921, 2008. doi:10.1111/j.1460-9592.2008.02764.x.
5. Astokorki AH, Mauger AR. Tolerance of exercise-induced pain at a fixed
rating of perceived exertion predicts time trial cycling performance. Scand
J Med Sci Sports 27: 309–317, 2017. doi:10.1111/sms.12659.
6. Bailey SJ, Wilkerson DP, Fulford J, Jones AM. Influence of passive
lower-body heating on muscle metabolic perturbation and high-intensity
exercise tolerance in humans. Eur J Appl Physiol 112: 3569–3576, 2012.
doi:10.1007/s00421-012-2336-6.
7. Black MI, Jones AM, Blackwell JR, Bailey SJ, Wylie LJ, McDon-
agh ST, Thompson C, Kelly J, Sumners P, Mileva KN, Bowtell JL,
Vanhatalo A. Muscle metabolic and neuromuscular determinants of fatigue
during cycling in different exercise intensity domains. J Appl Physiol (1985)
122: 446–459, 2017. doi:10.1152/japplphysiol.00942.2016.
R353EFFECT OF ACETAMINOPHEN ON CONTRALATERAL LEG FATIGUE
AJP-Regul Integr Comp Physiol • doi:10.1152/ajpregu.00084.2019 • www.ajpregu.org
Downloaded from www.physiology.org/journal/ajpregu at Loughborough Univ (158.125.080.117) on November 15, 2019.
8. Blain GM, Mangum TS, Sidhu SK, Weavil JC, Hureau TJ, Jessop JE,
Bledsoe AD, Richardson RS, Amann M. Group III/IV muscle afferents
limit the intramuscular metabolic perturbation during whole body exercise
in humans. J Physiol 594: 5303–5315, 2016. doi:10.1113/JP272283.
9. Borg GAV. An Introduction to Borgs RPE Scale. New York: Movement
Publications, 1985.
10. Broxterman RM, Layec G, Hureau TJ, Amann M, Richardson RS.
Skeletal muscle bioenergetics during all-out exercise: mechanistic insight
into the oxygen uptake slow component and neuromuscular fatigue. J Appl
Physiol (1985) 122: 1208–1217, 2017. doi:10.1152/japplphysiol.01093.
2016.
11. Broxterman RM, Layec G, Hureau TJ, Morgan DE, Bledsoe AD,
Jessop JE, Amann M, Richardson RS. Bioenergetics and ATP synthesis
during exercise: role of group III/IV muscle afferents. Med Sci Sports
Exerc 49: 2404–2413, 2017. doi:10.1249/MSS.0000000000001391.
12. Broxterman RM, Hureau TJ, Layec G, Morgan DE, Bledsoe AD,
Jessop JE, Amann M, Richardson RS. Influence of group III/IV muscle
afferents on small muscle mass exercise performance: a bioenergetics
perspective. J Physiol 596: 2301–2314, 2018. doi:10.1113/JP275817.
13. Cook DB, O’Connor PJ, Eubanks SA, Smith JC, Lee M. Naturally
occurring muscle pain during exercise: assessment and experimental
evidence. Med Sci Sports Exerc 29: 999–1012, 1997. doi:10.1097/
00005768-199708000-00004.
14. Doix AC, Lefèvre F, Colson SS. Time course of the cross-over effect of
fatigue on the contralateral muscle after unilateral exercise. PLoS One 8:
e64910, 2013. doi:10.1371/journal.pone.0064910.
15. Edwards LM, Tyler DJ, Kemp GJ, Dwyer RM, Johnson A, Hollo-
way CJ, Nevill AM, Clarke K. The reproducibility of 31-phosphorus
MRS measures of muscle energetics at 3 Tesla in trained men. PLoS One
7: e37237, 2012. doi:10.1371/journal.pone.0037237.
16. Elmer SJ, Amann M, McDaniel J, Martin DT, Martin JC. Fatigue
is specific to working muscles: no cross-over with single-leg cycling in
trained cyclists. Eur J Appl Physiol 113: 479–488, 2013. doi:10.1007/
s00421-012-2455-0.
17. Forrest JAH, Clements JA, Prescott LF. Clinical pharmacokinetics
of Paracetamol. Clin Pharmacokinet 7: 93–107, 1982. doi:10.2165/
00003088-198207020-00001.
18. Foster J, Mauger A, Thomasson K, White S, Taylor L. Effect of acet-
aminophen ingestion on thermoregulation of normothermic, non-febrile hu-
mans. Front Pharmacol 7: 54, 2016. doi:10.3389/fphar.2016.00054.
19. Foster J, Taylor L, Chrismas BCR, Watkins SL, Mauger AR. The
influence of acetaminophen on repeated sprint cycling performance. Eur J
Appl Physiol 114: 41–48, 2014. doi:10.1007/s00421-013-2746-0.
20. Gagnon P, Bussières JS, Ribeiro F, Gagnon SL, Saey D, Gagné N,
Provencher S, Maltais F. Influences of spinal anesthesia on exercise
tolerance in patients with chronic obstructive pulmonary disease. Am J Respir
Crit Care Med 186: 606–615, 2012. doi:10.1164/rccm.201203-0404OC.
21. Grabiner MD, Owings TM. Effects of eccentrically and concentrically
induced unilateral fatigue on the involved and uninvolved limbs. J
Electromyogr Kinesiol 9: 185–189, 1999. doi:10.1016/S1050-6411(98)
00031-5.
22. Halperin I, Copithorne D, Behm DG. Unilateral isometric muscle fatigue
decreases force production and activation of contralateral knee extensors
but not elbow flexors. Appl Physiol Nutr Metab 39: 1338–1344, 2014.
doi:10.1139/apnm-2014-0109.
23. Halperin I, Chapman DW, Behm DG. Non-local muscle fatigue:
effects and possible mechanisms. Eur J Appl Physiol 115: 2031–2048,
2015. doi:10.1007/s00421-015-3249-y.
24. Hayes SG, Kindig AE, Kaufman MP. Cyclooxygenase blockade atten-
uates responses of group III and IV muscle afferents to dynamic
exercise in cats. Am J Physiol Heart Circ Physiol 290: H2239 –H2246,
2006. doi:10.1152/ajpheart.01274.2005.
25. Hureau TJ, Romer LM, Amann M. The “sensory tolerance limit”: a
hypothetical construct determining exercise performance? Eur J Sport Sci
18: 13–24, 2018. doi:10.1080/17461391.2016.1252428.
26. Johnson MA, Sharpe GR, Williams NC, Hannah R. Locomotor muscle
fatigue is not critically regulated after prior upper body exercise. J Appl
Physiol (1985) 119: 840–850, 2015. doi:10.1152/japplphysiol.00072.
2015.
27. Kemp GJ, Roussel M, Bendahan D, Le Fur Y, Cozzone PJ. Interrela-
tions of ATP synthesis and proton handling in ischaemically exercising
human forearm muscle studied by 31P magnetic resonance spectroscopy. J
Physiol 535: 901–928, 2001. doi:10.1111/j.1469-7793.2001.00901.x.
28. Kennedy DS, Fitzpatrick SC, Gandevia SC, Taylor JL. Fatigue-related
firing of muscle nociceptors reduces voluntary activation of ipsilateral but
not contralateral lower limb muscles. J Appl Physiol (1985) 118: 408–418,
2015. doi:10.1152/japplphysiol.00375.2014.
29. Kennedy A, Hug F, Sveistrup H, Guével A. Fatiguing handgrip exercise
alters maximal force-generating capacity of plantar-flexors. Eur J Appl
Physiol 113: 559–566, 2013. doi:10.1007/s00421-012-2462-1.
30. Mauger AR, Jones AM, Williams CA. Influence of acetaminophen on
performance during time trial cycling. J Appl Physiol (1985) 108: 98–104,
2010. doi:10.1152/japplphysiol.00761.2009.
31. Morgan PT, Bowtell JL, Vanhatalo A, Jones AM, Bailey SJ. Acute
acetaminophen ingestion improves performance and muscle activation
during maximal intermittent knee extensor exercise. Eur J Appl Physiol
118: 595–605, 2018. doi:10.1007/s00421-017-3794-7.
32. Morgan PT, Vanhatalo A, Bowtell JL, Jones AM, Bailey SJ. Acet-
aminophen ingestion improves muscle activation and performance during
a 3-min all-out cycling test. Appl Physiol Nutr Metab 44: 434–442, 2019.
doi:10.1139/apnm-2018-0506.
33. Poole DC, Burnley M, Vanhatalo A, Rossiter HB, Jones AM.
Critical power: an important fatigue threshold in exercise physiology.
Med Sci Sports Exerc 48: 2320 –2334, 2016. doi:10.1249/MSS.
0000000000000939.
34. Rattey J, Martin PG, Kay D, Cannon J, Marino FE. Contralateral muscle
fatigue in human quadriceps muscle: evidence for a centrally mediated fatigue
response and cross-over effect. Pflugers Arch 452: 199–207, 2006. doi:10.
1007/s00424-005-0027-4.
35. Regueme SC, Barthèlemy J, Nicol C. Exhaustive stretch-shortening cycle
exercise: no contralateral effects on muscle activity in maximal motor per-
formances. Scand J Med Sci Sports 17: 547–555, 2007. doi:10.1111/j.1600-
0838.2006.00614.x.
36. Rossman MJ, Venturelli M, McDaniel J, Amann M, Richardson RS.
Muscle mass and peripheral fatigue: a potential role for afferent feedback?
Acta Physiol (Oxf) 206: 242–250, 2012. doi:10.1111/j.1748-1716.2012.
02471.x.
37. Rueff A, Dray A. Sensitization of peripheral afferent fibres in the in vitro
neonatal rat spinal cord-tail by bradykinin and prostaglandins. Neurosci-
ence 54: 527–535, 1993. doi:10.1016/0306-4522(93)90272-H.
38. Schaible HG, Ebersberger A, Natura G. Update on peripheral mecha-
nisms of pain: beyond prostaglandins and cytokines. Arthritis Res Ther 13:
210, 2011. doi:10.1186/ar3305.
39. Sidhu SK, Weavil JC, Mangum TS, Jessop JE, Richardson RS, Morgan
DE, Amann M. Group III/IV locomotor muscle afferents alter motor
cortical and corticospinal excitability and promote central fatigue during
cycling exercise. Clin Neurophysiol 128: 44–55, 2017. doi:10.1016/j.
clinph.2016.10.008.
40. Sidhu SK, Weavil JC, Thurston TS, Rosenberger D, Jessop JE, Wang
E, Richardson RS, McNeil CJ, Amann M. Fatigue-related group III/IV
muscle afferent feedback facilitates intracortical inhibition during loco-
motor exercise. J Physiol 596: 4789–4801, 2018. doi:10.1113/JP276460.
41. Sidhu SK, Weavil JC, Venturelli M, Garten RS, Rossman MJ,
Richardson RS, Gmelch BS, Morgan DE, Amann M. Spinal -opioid
receptor-sensitive lower limb muscle afferents determine corticospinal
responsiveness and promote central fatigue in upper limb muscle. J
Physiol 592: 5011–5024, 2014. doi:10.1113/jphysiol.2014.275438.
42. Takahashi K, Maruyama A, Hirakoba K, Maeda M, Etoh S, Kawa-
hira K, Rothwell JC. Fatiguing intermittent lower limb exercise influ-
ences corticospinal and corticocortical excitability in the nonexercised
upper limb. Brain Stimul 4: 90–96, 2011. doi:10.1016/j.brs.2010.07.001.
43. Todd G, Petersen NT, Taylor JL, Gandevia SC. The effect of a contralat-
eral contraction on maximal voluntary activation and central fatigue in elbow
flexor muscles. Exp Brain Res 150: 308–313, 2003. doi:10.1007/s00221-003-
1379-7.
44. Vanhatalo A, Fulford J, Bailey SJ, Blackwell JR, Winyard PG, Jones
AM. Dietary nitrate reduces muscle metabolic perturbation and im-
proves exercise tolerance in hypoxia. J Physiol 589: 5517–5528, 2011.
doi:10.1113/jphysiol.2011.216341.
45. Vanhatalo A, Fulford J, DiMenna FJ, Jones AM. Influence of hyper-
oxia on muscle metabolic responses and the power-duration relation-
ship during severe-intensity exercise in humans: a 31P magnetic reso-
nance spectroscopy study. Exp Physiol 95: 528 –540, 2010. doi:10.
1113/expphysiol.2009.050500.
46. Zijdewind I, Zwarts MJ, Kernell D. Influence of a voluntary fatigue
test on the contralateral homologous muscle in humans? Neurosci Lett
253: 41–44, 1998. doi:10.1016/S0304-3940(98)00609-0.
R354 EFFECT OF ACETAMINOPHEN ON CONTRALATERAL LEG FATIGUE
AJP-Regul Integr Comp Physiol • doi:10.1152/ajpregu.00084.2019 • www.ajpregu.org
Downloaded from www.physiology.org/journal/ajpregu at Loughborough Univ (158.125.080.117) on November 15, 2019.
